Skip to main content

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

2
Pipeline Programs
4
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Prevail Therapeutics
1 program
1
LY3650150Phase 31 trial
Active Trials
NCT06338995Recruiting510Est. Mar 2028
Longbio Pharma
Longbio PharmaChina - Shanghai
1 program
1
LP-003 InjectionPhase 21 trial
Active Trials
NCT07313917Not Yet Recruiting150Est. Sep 2027
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Biologic drugsN/A1 trial
Active Trials
NCT06617754Active Not Recruiting3,000Est. Jan 2032
Chia Tai TianQing Pharmaceutical Group
1 program
TQC2731 injectionPHASE_31 trial
Active Trials
NCT07107256Recruiting246Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
2031
Chia Tai TianQing Pharmaceutical GroupTQC2731 injection
Prevail TherapeuticsLY3650150
Longbio PharmaLP-003 Injection
Allergy TherapeuticsBiologic drugs

Clinical Trials (4)

Total enrollment: 3,906 patients across 4 trials

NCT07107256Chia Tai TianQing Pharmaceutical GroupTQC2731 injection

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

Start: Sep 2025Est. completion: Sep 2027246 patients
Phase 3Recruiting
NCT06338995Prevail TherapeuticsLY3650150

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Start: Apr 2024Est. completion: Mar 2028510 patients
Phase 3Recruiting
NCT07313917Longbio PharmaLP-003 Injection

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Start: Jan 2026Est. completion: Sep 2027150 patients
Phase 2Not Yet Recruiting
NCT06617754Allergy TherapeuticsBiologic drugs

International Severe CRSwNP Registry 2024-2028

Start: Mar 2025Est. completion: Jan 20323,000 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 3,906 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.